C4 Therapeutics (CCCC) Q1 Loss Of US$25.1 Million Reinforces Profitability Concerns

C4 Therapeutics (CCCC) has opened 2026 with Q1 revenue of US$6.2 million and a basic EPS loss of US$0.20, alongside a trailing twelve month revenue base of US$34.9 million and a net loss of US$103.8 million, setting a clear tone for how the market will read the latest update. Over recent quarters the company has seen revenue move between US$5.2 million in Q4 2024 and US$11.2 million in Q3 2025, while quarterly basic EPS has ranged from a loss of US$0.18 to a loss of US$0.49. This print keeps the focus squarely on how much pressure remains on margins rather than on any top line surprise, with investors weighing that against forecasts for strong revenue growth.

See our full analysis for C4 Therapeutics.

With the headline numbers on the table, the next step is to set them against the key narratives around C4 Therapeutics to see which stories about growth, risk, and profitability still hold up and which ones start to look stretched.

Curious how numbers become stories that shape markets? Explore Community Narratives

TTM loss of US$103.8 million keeps profitability in focus

• On a trailing twelve month basis, C4 Therapeutics reported total revenue of US$34.9 million against a net loss of US$103.8 million, with the latest Q1 2026 quarter alone showing revenue of US$6.2 million and a net loss of US$25.1 million.
• Critics highlight that earnings are expected to decline by about 7.1% per year over the next three years while the company is already reporting quarterly losses between roughly US$20.5 million and US$34.6 million in the last six reported periods. This supports a bearish focus on ongoing profit pressure but also means any improvement in loss levels could challenge the most pessimistic expectations.
  • The trailing twelve month loss of US$103.8 million sits close to the US$104.0 million loss level seen one year earlier, which aligns with concerns that profitability has not moved into a clearly improving trend yet.
  • Basic EPS over the last year, at a trailing twelve month loss of US$1.07 per share compared with a loss of US$1.52 per share at the end of 2024, gives bears data to point to continued losses while also leaving room for bulls to argue that per share losses have not been steadily worsening.

Revenue growth forecasts near 35.9% contrasted with choppy quarterly sales

• Revenue has moved between US$5.2 million and US$11.2 million per quarter over the last six reported periods, while forecasts point to revenue growth of about 35.9% per year over the coming years compared with an 11.6% growth rate for the wider US market.
• Supporters of a bullish view point to the 35.9% revenue growth forecast as the key attraction, yet the recent pattern of quarterly revenue between US$6.2 million and roughly US$11.2 million across 2025 and early 2026 means the current revenue base is still modest and testing how quickly that growth story can show up in reported numbers.
  • The trailing twelve month revenue of US$34.9 million is similar to the US$35.9 million level a year earlier, so the strong forward growth forecast is not yet mirrored in trailing figures, which keeps attention on future contract and milestone timing.
  • Across 2025, revenue ranged from US$6.5 million to about US$11.2 million per quarter, so any shift toward the upper end of that band, or above it, would more clearly support bullish expectations for faster top line expansion.

Investors who want to see how these growth forecasts and loss levels are feeding into different storylines about C4 Therapeutics can use the narrative tools to connect the numbers to longer term theses Curious how numbers become stories that shape markets? Explore Community Narratives

P/S of 11.6x sits between peers and wider biotech

• C4 Therapeutics is trading on a P/S of 11.6x, which is below its direct peer group average of 16.8x but above the broader US biotech industry average of 9.7x, while the current share price is US$3.68.
• Bears argue that persistent losses plus recent shareholder dilution justify caution even at this P/S level, and the combination of a trailing twelve month loss of US$103.8 million with share issuance over the past year supports concerns that valuation needs to be weighed carefully against ongoing unprofitability rather than only against relative P/S comparisons.
  • The company has remained unprofitable over the last twelve months with a basic EPS loss of US$1.07 per share and is forecast to remain loss making over the next three years, which aligns with the more cautious stance on how much investors should pay per dollar of sales.
  • Substantial dilution in the past year, alongside a share price that has been more volatile than the US market over the last three months, gives bears concrete examples of how funding and sentiment risks can feed back into returns even when revenue outlooks appear strong.

Next Steps

Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on C4 Therapeutics's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move.

If the mix of forecasts, losses, and valuation still feels finely balanced, now is the time to check the underlying data and stress test your own view, referring to 1 key reward and 4 important warning signs.

See What Else Is Out There

C4 Therapeutics is still reporting sizeable losses, a modest revenue base and shareholder dilution, so profitability and valuation risk remain front of mind.

If you want ideas that prioritize stronger fundamentals and potentially more supportable valuations, check out the solid balance sheet and fundamentals stocks screener (46 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com